INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Tr... - 07 January 2021 00:00

PLYMOUTH MEETING, Pa., Jan. 6, 2021 /PRNewswire-AsiaNet/ -- -- DNA immunotherapy candidate VGX-3100 demonstrated clinically significant reduction of HPV-16/18-associated precancerous vulvar lesions in 63% of treated participants six months after treatment -- Phase 2 results indicate that...

  RedHill Biopharma's RHB-204 Granted FDA Fast Track Designation... - 06 January 2021 23:44

TEL AVIV, Israel and RALEIGH, NC, Jan. 6, 2021 /PRNewswire-AsiaNet / -- U.S. Phase 3 study underway to evaluate RHB-204 as a first-line, stand-alone, oral treatment for pulmonary NTM disease - a rare condition with no FDA-approved first-line therapy FDA Fast Track designation, together with previously granted QIDP...

  Eleva Secures up to EUR 60 million to Advance a Drug Candidate... - 06 January 2021 20:00

FREIBURG, Germany, January 6, 2021, /PRNewswire-AsiaNet/-- Eleva, a manufacturer of superior biologics, has secured up to EUR 60 million in funding from Zukunftsfonds Heilbronn (ZFHN). The funds will help advance one of its drug candidates, CPV-101, to stages that will facilitate further investment from v...

  Gift of Life Donor Program Leads U.S. in Organ Donation for 13... - 06 January 2021 00:12

PHILADELPHIA, Jan. 5, 2021 /PRNewswire-AsiaNet/ -- -- Region Demonstrates Extraordinary Generosity and Clinical Leadership Despite Pandemic Challenges: Most Organ Donors Every Year Since 2008 For the 13th consecutive year, Gift of Life Donor Program leads the nation in the most organ donors amo...

  INOVIO and Advaccine Announce Exclusive Partnership To Commerc... - 05 January 2021 00:00

PLYMOUTH MEETING, Pa. and SUZHOU, China, Jan. 4, 2021 /PRNewswire-AsiaNet/ -- - Partnership Adds Asian Manufacturing Resource to INOVIO's Global Manufacturing Consortium for INO-4800 - INO-4800 Phase 2 Trial Fully Enrolled in China INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely d...

  RedHill Biopharma Announces Positive Top-Line Safety and Effic... - 01 January 2021 09:39

TEL AVIV, Israel and RALEIGH, N.C., Dec. 31, 2020 /PRNewswire-AsiaNet/ -- - Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms - Consistent trends demonstrate great...

  WinHealth and Immedica enter agreement giving Winhealth rights... - 31 December 2020 12:00

STOCKHOLM and HANGZHOU, China, Dec. 31, 2020 /PRNewswire-AsiaNet/ -- Hongkong WinHealth Pharma Group CO., Ltd and Immedica Pharma AB, today announce that they have entered an agreement under which WinHealth gains the exclusive commercial rights to Ravicti(R) (glycerol phenylbutyrate), in a territory covering the Gr...

  EW Nutrition launches new xylanase enzyme in Malaysia - 28 December 2020 23:04

SINGAPORE, Dec. 28, 2020 /PRNewswire-AsiaNet/ -- In its continued efforts to reduce antibiotic use in the region while also improving farm profitability, EW Nutrition launched Axxess(R) XY in Malaysia on December 17, 2020. Axxess(R) XY is a next-generation intrinsically thermostable x...

  Closer China-Japan Health Cooperation for Healthier Mankind an... - 25 December 2020 18:38

BEIJING, Dec. 25, 2020 /PRNewswire-AsiaNet/ -- - China-Japan Health Forum for the New Era held by Global Health Forum of Boao Forum for Asia The China-Japan Health Forum for the New Era co-sponsored by Global Health Forum of Boao Forum for Asia and Nippon Global Medical Organization was h...

  INOVIO Announces Publication of Phase 1 Data from its COVID-19... - 25 December 2020 02:19

PLYMOUTH MEETING, Pa., Dec. 24, 2020 /PRNewswire-AsiaNet/ -- -- Peer-reviewed Phase 1 data shows INO-4800 to be immunogenic in 100% of subjects, inducing neutralizing antibody and/or T cell responses -- INO-4800 demonstrates favorable safety and tolerability, with no serious adverse events reported --...